Vir Biotechnology Inc
Prices are adjusted according to historical splits.
- Today's Low:
- Today's High:
- Open Price:
- 52W Low:
- 52W High:
- Prev. Close:
- Market Cap.:
- $1.68 billion
- Book Value:
- Revenue TTM:
- $490.72 million
- Operating Margin TTM:
- Gross Profit TTM:
- $1.03 billion
- Profit Margin:
- Return on Assets TTM:
- Return on Equity TTM:
Vir Biotechnology Inc had its IPO on 2019-10-11 under the ticker symbol VIR.
The company operates in the Healthcare sector and Biotechnology industry. Vir Biotechnology Inc has a staff strength of 576 employees.
Shares of Vir Biotechnology Inc opened at $10.68 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $10.47 - $10.82, and closed at $10.49.
This is a -2.24% slip from the previous day's closing price.
A total volume of 1,689,807 shares were traded at the close of the day’s session.
In the last one week, shares of Vir Biotechnology Inc have slipped by -16.15%.
Vir Biotechnology Inc's Key Ratios
Vir Biotechnology Inc has a market cap of $1.68 billion, indicating a price to book ratio of 1.6037 and a price to sales ratio of 1.4094.
In the last 12-months Vir Biotechnology Inc’s revenue was $490.72 million with a gross profit of $1.03 billion and an EBITDA of $-255975008. The EBITDA ratio measures Vir Biotechnology Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Vir Biotechnology Inc’s operating margin was -55.02% while its return on assets stood at -6.94% with a return of equity of -13.93%.
In Q2, Vir Biotechnology Inc’s quarterly earnings growth was a positive 58.5% while revenue growth was a negative 94.9%.
Vir Biotechnology Inc’s PE and PEG Ratio
- Forward PE
- Trailing PE
Its diluted EPS in the last 12-months stands at $-1.9 per share while it has a forward price to earnings multiple of 4.3611 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Vir Biotechnology Inc’s profitability.
Vir Biotechnology Inc stock is trading at a EV to sales ratio of 0.5203 and a EV to EBITDA ratio of 0.7891. Its price to sales ratio in the trailing 12-months stood at 1.4094.
Vir Biotechnology Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $2.24 billion
- Total Liabilities
- $225.62 million
- Operating Cash Flow
- $230.32 million
- Capital Expenditure
- $9.46 million
- Dividend Payout Ratio
Vir Biotechnology Inc ended 2023 with $2.24 billion in total assets and $0 in total liabilities. Its intangible assets were valued at $2.24 billion while shareholder equity stood at $1.81 billion.
Vir Biotechnology Inc ended 2023 with $0 in deferred long-term liabilities, $225.62 million in other current liabilities, 13000.00 in common stock, $41.56 million in retained earnings and $16.94 million in goodwill. Its cash balance stood at $666.95 million and cash and short-term investments were $1.85 billion. The company’s total short-term debt was $13,536,000 while long-term debt stood at $0.
Vir Biotechnology Inc’s total current assets stands at $1.95 billion while long-term investments were $52.36 million and short-term investments were $1.18 billion. Its net receivables were $16.85 million compared to accounts payable of $12.36 million and inventory worth $0.
In 2023, Vir Biotechnology Inc's operating cash flow was $230.32 million while its capital expenditure stood at $9.46 million.
Comparatively, Vir Biotechnology Inc paid $0 in dividends in 2023.
Other key metrics
- Current Trading Price
- 52-Week High
- 52-Week Low
- Analyst Target Price
Vir Biotechnology Inc stock is currently trading at $10.49 per share. It touched a 52-week high of $31.55 and a 52-week low of $31.55. Analysts tracking the stock have a 12-month average target price of $33.88.
Its 50-day moving average was $15.5 and 200-day moving average was $22.98 The short ratio stood at 2.65 indicating a short percent outstanding of 0%.
Around 1425.7% of the company’s stock are held by insiders while 7595.1% are held by institutions.
Frequently Asked Questions About Vir Biotechnology Inc
Similar Industry Stocks (Biotechnology)
Vir Biotechnology, Inc., a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops Sotrovimab (VIR-7832), a SARS-CoV-2-neutralizing mAbs to treat and prevent COVID-19 infection under the Xevudy brand; VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 for the prevention of influenza A virus; and VIR-1111 for the prevention of human immunodeficiency virus. The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited and Brii Biosciences Offshore Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with MedImmune; collaboration with WuXi Biologics and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals SA. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. for the manufacture of SARS-COV-2 antibodies; and clinical collaboration with Gilead Sciences, Inc. for chronic hepatitis B virus. The company was incorporated in 2016 and is headquartered in San Francisco, California.